Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Radical brain surgery for glioblastoma: could a wider cut save lives?

NCT ID NCT04243005

Disease control Sponsor: St. Olavs Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests whether removing a wider margin of brain tissue around a glioblastoma tumor (supramarginal resection) improves survival compared to standard surgery. It involves 90 patients with suspected glioblastoma who are considered good candidates for the more extensive surgery. The goal is to see if this aggressive approach, guided by MRI, can extend life without causing unacceptable harm.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Supramarginal resection (surgery that removes a margin of at least 10 mm beyond the visible tumor)
What this could lead to
If it works, this could show that removing more tissue around the tumor helps people with glioblastoma live longer.
What could go wrong
This is a small, early-stage trial with only 90 patients. Removing more brain tissue may cause neurological problems, and the benefit is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2020

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. A suspected diagnosis of supratentorial glioblastoma by MRI.(A) 2. Indication for surgical treatment and where supramarginal resection is considered possible according to the preoperative imaging. This consideration needs to be verified by two specialists in neurosurgery. 3. Negative work-up for other primary tumor(B) 4. Karnofsky performance status of 70 - 100. A) If randomized to supramarginal surgery, intraoperative frozen section must conclude with "high-grade glioma" to be able to proceed. Surgery in two sessions is also possible in supramarginal group if there is no intraoperative frozen section available or frozen section indicate another diagnosis, but final histopathology reveals a glioblastoma. In case of surgery in two session, there must be no more than 30 days between procedures. See flow-chart in attachment 1. B) No suspected primary tumor seen on CT chest, abdomen and pelvis. If relevant symptoms/clinical suspicion also supplement with mammography, dermatologist exam, relevant endoscopies etc. Exclusion Criteria: 1. Not willing to be randomized. 2. Informed consent not possible (e.g. language barriers, aphasia, cognitive severely impaired). 3. Contrast enhancement volume bilateral OR involving corpus callosum. 4. Contrast enhancement along the ependymal lining of ventricles (contact is however not an exclusion criteria). 5. Contrast enhancement involving several lobes. 6. History of major psychiatric disorder such as psychosis, schizophrenia and/or mood disorder (e.g. depression and bipolar disorder) in need of hospitalization 7. Unfit for participation for any other reason judged by the including physician

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glioblastoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glioblastoma

Contacts and locations

Locations

  • Erasmus MC

    Rotterdam, Netherlands

  • Haaglanden MC

    The Hague, Netherlands

  • Haukeland University Hospital

    Bergen, Norway

  • Helsinki University Hospital

    Helsinki, Finland

  • Karolinska University Hospital

    Stockholm, Sweden

  • Kuopio University Hospital

    Kuopio, Finland

  • Medical University of Vienna

    Vienna, Austria

  • Odense University Hospital

    Odense, Denmark

  • Oslo University Hospital, Rikshospitalet

    Oslo, Norway

  • Oulu University Hospital

    Oulu, Finland

  • Sahlgrenska University Hospital,

    Gothenburg, Sweden

  • St Olavs Hospital

    Trondheim, Norway

  • Tampere University Hospital

    Tampere, Finland

  • Turku University Hospital

    Turku, Finland

  • Ullevål University Hospital

    Oslo, Norway

  • University Hospital of Umeå

    Umeå, Sweden

  • Uppsala University Hospital

    Uppsala, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.